Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

Abstract Alveolar soft part sarcoma (ASPS) is an ultra-rare, highly angiogenic sarcoma with limited responsiveness to chemotherapy. Tyrosine kinase inhibitors (TKIs) such as sunitinib and pazopanib have shown promising activity, but comparative real-world data remain scarce. This multicenter, retros...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Zehra Sucuoğlu İşleyen, Seval Ay, Ertuğrul Bayram, Şaban Seçmeler, Oğuzhan Selvi, Saadettin Kılıçkap, Deniz Can Güven, Sabin Göktaş Aydın, Teoman Sakalar, Metin Pehlivan, Serkan Keskin, Olçun Ümit Ünal, Serkan Menekşe, Engin Kut, Eyyup Çavdar, Özlem Aydın İsak, İsmail Ertürk, Emre Hafızoğlu, Murat Ayhan, Nurgül Yaşar, Seval Orman, Hatice Asoğlu Rüzgar, Reşit Akyel, Mert Başaran, Kayhan Ertürk, M. Mustafa Atcı, Emir Çelik
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Portfolio 2025-11-01
سلاسل:	Scientific Reports
الموضوعات:	Alveolar soft part sarcoma Sunitinib Pazopanib Tyrosine kinase inhibitor Anti-angiogenic therapy
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41598-025-29276-9
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!